Corient Private Wealth LLC Sells 3,172 Shares of Icon Plc $ICLR

Corient Private Wealth LLC trimmed its holdings in shares of Icon Plc (NASDAQ:ICLR) by 6.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 49,137 shares of the medical research company’s stock after selling 3,172 shares during the quarter. Corient Private Wealth LLC owned approximately 0.06% of Icon worth $8,954,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Toth Financial Advisory Corp bought a new stake in Icon during the 4th quarter valued at $27,000. EFG International AG purchased a new position in shares of Icon in the 4th quarter valued at $27,000. Ameriflex Group Inc. bought a new position in shares of Icon in the 3rd quarter worth $33,000. Abound Financial LLC bought a new position in shares of Icon in the 4th quarter worth $54,000. Finally, Johnson Financial Group Inc. purchased a new stake in shares of Icon during the 3rd quarter worth $71,000. Institutional investors own 95.61% of the company’s stock.

Icon Trading Up 10.9%

Icon stock opened at $158.17 on Thursday. The stock has a 50-day moving average price of $127.61 and a 200 day moving average price of $138.23. The company has a market capitalization of $12.11 billion, a price-to-earnings ratio of 28.14, a price-to-earnings-growth ratio of 11.70 and a beta of 1.26. Icon Plc has a 52 week low of $66.57 and a 52 week high of $211.00. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.31.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Tuesday, June 23rd. The medical research company reported $2.50 earnings per share for the quarter, topping the consensus estimate of $2.43 by $0.07. Icon had a net margin of 5.35% and a return on equity of 8.71%. The company had revenue of $2.03 billion for the quarter, compared to the consensus estimate of $1.98 billion. During the same quarter in the prior year, the company earned $3.43 EPS. Icon’s quarterly revenue was up 2.5% on a year-over-year basis. Sell-side analysts anticipate that Icon Plc will post 9.38 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ICLR. Bank of America reiterated an “outperform” rating on shares of Icon in a research note on Monday, June 1st. Citigroup increased their price target on shares of Icon from $120.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, May 29th. UBS Group set a $160.00 price target on shares of Icon in a report on Wednesday. Weiss Ratings downgraded shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, May 29th. Finally, TD Cowen boosted their price objective on shares of Icon from $120.00 to $164.00 and gave the stock a “buy” rating in a research note on Monday, June 1st. Eight analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $153.31.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.